[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362279-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362279-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dynamics-of-anal-hpv-infection-after-9vhpv-vaccination-in-men-who-have-sex-with-men-msm-with-hiv-a-prospective-controlled-cohort-study","Dynamics of Anal HPV Infection After 9vHPV Vaccination in Men Who Have Sex with Men (MSM) With HIV - A Prospective, Controlled Cohort Study","","Men who have sex with men (MSM) living with HIV face disproportionate burden from persistent human papillomavirus (HPV) infection and HPV-associated anogenital cancers. A prospective controlled cohort study evaluated whether a 3-dose nonavalent HPV vaccine (9vHPV) improves HPV clearance and reduces incidence of vaccine-covered types. Anal specimens underwent HPV genotyping, cytology, and microbiota profiling. Baseline vaccine-type HPV prevalence was similar between groups, but vaccination was not associated with enhanced clearance or lower incidence, and no meaningful 12-month dysplasia or microbiota changes were observed. Continued routine anal cancer screening is required.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dynamics-of-anal-hpv-infection-after-9vhpv-vaccination-in-men-who-have-sex-with-men-msm-with-hiv-a-prospective-controlled-cohort-study/362279/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dynamics-of-anal-hpv-infection-after-9vhpv-vaccination-in-men-who-have-sex-with-men-msm-with-hiv-a-prospective-controlled-cohort-study/362279.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What study design was used to evaluate 9vHPV in MSM with HIV?","Question",{"text":63,"@type":64},"A prospective, controlled cohort study followed eligible MSM with HIV who received a 3-dose 9vHPV series (vaccinees) and compared them with unvaccinated controls.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What were the primary outcomes assessed in the study?",{"text":68,"@type":64},"The primary outcomes were clearance and incidence of HPV types covered by the 9vHPV vaccine, assessed using anal specimens with HPV genotyping and related measures.",{"name":70,"@type":61,"acceptedAnswer":71},"Did 9vHPV vaccination improve HPV clearance or reduce HPV incidence?",{"text":72,"@type":64},"No. 9vHPV vaccination was not associated with enhanced clearance or decreased incidence of vaccine-type HPV, and no significant differences were seen in anal dysplasia regression or anal microbiota composition over 12 months.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362279,1790168473,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","HUMAN VACCINES & IMMUNOTHERAPEUTICS 2026, VOL. 22, NO. 1, 2618876 [https://doi.org/10.1080/21645515.2026.2618876](https://doi.org/10.1080/21645515.2026.2618876)  \nRESEARCH ARTICLE     \nDynamics of anal HPV infection after 9vHPV vaccination in men who have sex with men (MSM) with HIV: A prospective, controlled cohort study  \nKuan-Yin Lina,b, Shuo-Lun Laic, Yu-Shan Huanga, Hsin-Yu Suna, Yu-Chung Chuanga, I-Shiow Jand, WenChun Liua, Chi-Tai Fang a,b,e*, and Chien-Ching Hunga,f,g*  \naDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan, University College of Medicine, Taipei, Taiwan; bInstitute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan; cDepartment of Surgery, National Taiwan University Hospital and National Taiwan, University College of Medicine, Taipei, Taiwan; dDepartment of Laboratory Medicine, National Taiwan University Hospital and National, Taiwan University College of Medicine, Taipei, Taiwan; e National Taiwan University School of Medicine, Taipei, Taiwan; fDepartment of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan; gDepartment of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan  \nABSTRACT  \nMen who have sex with men (MSM) with HIV are disproportionately affected by persistent human papillomavirus (HPV) infections and related anogenital cancers. No controlled trial has evaluated the efficacy of the nonavalent HPV vaccine (9vHPV) in this population. This prospective, controlled cohort study offered eligible MSM with HIVa 3-dose 9vHPV series and followed both the vaccinated group (vaccinees) and the unvaccinated group (controls) . Anal specimens were collected for HPV genotyping, cytology, and microbiota profiling. The primary outcomes were the clearance and incidence of 9vHPV-covered HPV types. Baseline vaccine-type HPV prevalence was 41.0% in vaccinees (n = 39; median age, 33 y; median CD4, 682/μl) and 39.3% in controls (n = 56; median age, 35 y; median CD4, 679/μl) (P = .865) . At month 3, 75.0% of vaccinees with prevalent HPV infection had cleared at least one genotype, and 85.7% of those with abnormal baseline cytology experienced regression. However, clearance rates (per 1000 person-months) were 46.3 (vaccine type) and 56.0 (non-vaccine type) in vaccinees versus 64.1 and 91.8 in controls (P = .456 and 0.371) . HPV incidence was 19.5 (vaccine type) and 15.1 (non-vaccine type) in vaccinees versus 12.4 and 12.4 in controls (P = .378 and 0. 710) . 9vHPV vaccination was not associated with enhanced clearance (aHR, 0.27; 95% CI, 0.11–0.68) or decreased incidence of vaccine-type HPV (aHR, 0.44; 95% CI, 0.11–1.82) . No significant differences were observed in anal dysplasia regression or anal microbiota composition over 12 months. Given the lack of short-term secondary benefit and persistence of HPV incidence, MSM with HIV require continued routine anal cancer screening.  \nARTICLE HISTORY  \nReceived 25 September 2025 Revised 1 January 2026 Accepted 14 January 2026  \nKEYWORDS  \nClearance; regression; anal cytology; precancerous lesion; anal cancer screening; microbiota; sexually transmitted infection  \nIntroduction  \nHuman papillomavirus (HPV) infection, associated with invasive cancer, represents an important burden of disease.1 Men who have sex with men (MSM) with HIV are disproportionately affected by HPV infection and HPV-associated anogenital cancers, with a prevalence of high-risk (oncogenic) HPV genotype infections up to 74% .2 MSM with HIV are 20-fold more likely to acquire high-risk HPV than HIV-negative heterosexual men, and less likely to clear high-risk HPV infection.3 They have an estimated four-to 20-fold increase in incidence of anal cancer compared with the general population.4,5 These sharp disparities highlight the urgent need for effective preventive strategies, against HPV infection and associated diseases, in this v","cbCailVnnGb5nNmO","https://ap.wps.com/l/cbCailVnnGb5nNmO","pdf",1539750,"English","# Abstract\n# Introduction\n## Background and disease burden\n## Rationale for 9vHPV in MSM with HIV\n# Methods and outcomes (from abstract)","[{\"question\":\"What study design was used to evaluate 9vHPV in MSM with HIV?\",\"answer\":\"A prospective, controlled cohort study followed eligible MSM with HIV who received a 3-dose 9vHPV series (vaccinees) and compared them with unvaccinated controls.\"},{\"question\":\"What were the primary outcomes assessed in the study?\",\"answer\":\"The primary outcomes were clearance and incidence of HPV types covered by the 9vHPV vaccine, assessed using anal specimens with HPV genotyping and related measures.\"},{\"question\":\"Did 9vHPV vaccination improve HPV clearance or reduce HPV incidence?\",\"answer\":\"No. 9vHPV vaccination was not associated with enhanced clearance or decreased incidence of vaccine-type HPV, and no significant differences were seen in anal dysplasia regression or anal microbiota composition over 12 months.\"}]","Dynamics of Anal HPV Infection After 9vHPV Vaccination in Men Who Have Sex with Men (MSM) With HIV - A Prospective, Controlled Cohort Study | PDF",1790146942,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0491d730a4060dadf449c3fbb45ccf1.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df9287b2661def80834e13bc31ef6c36.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c6bb98160c15d0e92c03cfd9714b1de.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe5dd4793bec79265569855684d6ed1b.webp",980,1306]